Month: August 2023

Sylogist Reports 21% Y/Y Organic Growth and 26% Adjusted EBITDA Margin for Q2 ‘23

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Q2 2023 Financial HighlightsSylogist Ltd.CALGARY, Alberta, Aug. 10, 2023 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, today announced its Q2 financial results for the three months ending June 30, 2023. Q2 2023 Financial HighlightsRecord revenue of $16.7 million, up 21% Y/Y Recurring revenue up 8%; SaaS revenues up 9% Y/Y Gross margin at 61% Adjusted EBITDA of $4.3 million or 26% Adjusted EBITDA margin Bookings of $6.1 million Backlog of $28.9 million“The strong results we delivered in Q2 are further evidence of the successful transformation of our business over the last two years,” commented Bill Wood, CEO of Sylogist. “For investors, the strategic investments we’ve made and our focus on customer satisfaction, combined with...

Water Purifier Market Projected to Reach USD 54.48 Bn by 2030 | Striking CAGR 7.6%

Written by Customer Service on August 10, 2023. Posted in Mergers And Acquisitions.

The global water purifier market covered major segments by Product Type (Point-of-use Filters {Under the Counter Filters, Counter Top Filters, Pitcher Filters, Faucet-mounted Filters, and Others} and Point-of-entry Filters), By Category (RO Filters, UV Filters, Gravity Filters, and Others), By Application (Residential and Light Commercial) and region. Pune, India, Aug. 10, 2023 (GLOBE NEWSWIRE) — The global water purifier market size was USD 30.62 billion in 2022 and is anticipated to expand from USD 33.65 billion in 2023 to USD 54.48 billion by 2030, exhibiting a CAGR of 7.6% over the forecast period. The surge is driven by the availability of various purifiers with a range of technologies such as ultra-violet, reverse osmosis, and gravity-based purification processes. This information is provided by Fortune Business Insights™...

Check Point to Acquire Perimeter 81 – to Deliver the Fastest and most Secure SASE Solution in the Industry

Written by Customer Service on August 10, 2023. Posted in Mergers And Acquisitions.

SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, signs a definitive agreement to acquire Perimeter 81, a pioneering Security Service Edge (SSE) company. With this acquisition, Check Point will help organizations accelerate the adoption of secure access across remote users, sites, cloud, datacentres, and the internet, all while aiming to deliver the most secure and fastest SSE solution in the market. Under the terms of the agreement, Check Point will acquire Perimeter 81 for approximately $490 million, on a cash free, debt free basis. Hybrid work is now the standard of organizations globally, and digital transformation is continuously shifting data centers to the cloud. This major shift requires an advanced approach...

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to be encouraged by the therapeutic potential of our pipeline of oncology drug candidates that have shown clinical activity across multiple hard-to-treat solid tumor cancers,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “With multiple clinical trials underway, we are well-positioned for a number of upcoming data catalysts. We expect to announce additional clinical and immunological biomarker data from our phase 2 clinical trial in late...

Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended June 30, 2023

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Oxford Square Also Announces Declaration of Distributions on Common Stock for the Months Ending October 31, November 30, and December 31, 2023 and a Special Distribution of $0.12 Per Share Payable on September 29, 2023 GREENWICH, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQL) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended June 30, 2023.On August 3, 2023, our Board of Directors declared the following distributions on our common stock:Month Ending Record Date Payment Date Amount Per ShareSeptember 30, 2023* September 15, 2023 September 29, 2023 $ 0.120October 31, 2023 October 17, 2023 October 31, 2023 $ 0.035November 30, 2023 November 16, 2023 November...

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

– Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc® – Three product approvals achieved in Canada for FemaSeed®, FemCerv® and FemCath® products during the second quarter – Raised $3.9 million in a registered direct offering ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The past quarter, we made significant, notable progress on all fronts to advance our synergistic programs...

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)):XACIATO™ First Commercial Sale Ovaprene® (hormone-free monthly contraception) – Pivotal Phase 3 Contraceptive Efficacy Study – Patient Enrollment to Begin 4Q2023 Sildenafil Cream, 3.6% (female sexual arousal disorder and female sexual interest/arousal disorder) – preparations for end-of-Phase 2 meeting with FDA DARE-PDM1 (primary dysmenorrhea) – Phase 1 Clinical Study Topline Data Menopause programs: IND related activities for DARE-HRT1 (vasomotor symptoms of menopause) and DARE-VVA1 (vulvovaginal atrophy, a common condition in postmenopausal women, including those whose menopause resulted from receiving certain breast cancer treatments); Phase 3 and Phase 2 clinical study initiation plans, respectivelySAN DIEGO,...

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by year end 2023 Underwritten public offering and acquisition of Pionyr add over $80M to balance sheet BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended June 30, 2023. The Company also provided pipeline and corporate updates from the quarter and recent months. “It has been a busy time at Ikena, with new high-quality investors and peers sharing our confidence in our targeted oncology pipeline translating to important corporate milestones. We are in...

Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation...

Where Food Comes From, Inc. Reports 2023 Second Quarter Financial Results

Written by Customer Service on August 10, 2023. Posted in Earnings Releases And Operating Results.

Second Quarter Highlights – 2023 vs. 2022Revenue increased 15% to $6.1 million from $5.3 millionNet income increased 140% to $532,000 from $222,000Diluted EPS of $0.09 vs. $0.04Adjusted EBITDA increased 61% to $917,000 from $570,000Company buys back $836,000 of its stock in Q2, or 61,000 shares at average price of $13.70 per shareSix-Month Highlights – 2023 vs. 2022Revenue decreased 1% to $11.4 million from $11.5 million based on anomalous Q1 eventsNet income of $653,000 vs. $719,000Diluted EPS of $0.11 vs. $0.12Adjusted EBITDA of $1.3 million vs. $1.5 millionCash generated from operations declined to $1.3 million from $2.3 millionCash & cash equivalents at $3.4 million vs. $4.4 million at 2022 year-end, reflecting impact of stock buybacksCompany buys back more than $2.0 million of its stock through first...

Month: August 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals